Table 3.
The concentrations of tested biomarkers in patients with COVID-19 treated with dexamethasone and without such treatment.
| Variables | Group A without dexamethasone (n = 22) | p value gr.A v.1 vs. v.2 | Group B with dexamethasone (n = 14) | p value gr.B v.1 vs. v.2 | ||
|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 1 | Visit 2 | |||
| YKL-40, ng/ml (median, range) | 36.63 (8.31-185.86) | 37.11 (8.98-279.29) | 0.566 | 59.56 (17.25-177.45) | 33.66 (15.52-233.43) | 0.05 |
| YKL-40 1:2 ratio, (median, range) | 0.77 (0.13–2.30) | 1.41 (0.32–5.50) | ||||
| MR-pro-ADM, pmol/l (median, range) | 635.48 (127.11-1757.72) | 475.15 (338.22-1485.09) | 0.130 | 620.52 (174.27-2173.03) | 536.33 (194.91-2393.74) | 0.509 |
| MR-pro-ADM 1:2 ratio, (median, range) | 1.16 (0.38–1.75) | 1.10 (0.38–3.96) | ||||
Abbreviations: MR-pro-ADM - Mid regional pro-adrenomedullin, YKL-40 - Chitinase-3-like protein 1.